文献速递脊柱外科骨肿瘤

比较七种评分系统预测肺癌脊柱转移患者生存的准确性:来自两个中心的外部验证

Comparing the Accuracy of Seven Scoring Systems in Predicting Survival of Lung Cancer Patients With Spinal Metastases: An External Validation From Two Centers.
PubMed 文献 · Spine (Phila Pa 1976) · 2023-03-30

回顾性分析2019至2021年两个中心166例接受脊柱手术的肺癌脊柱转移患者,评估七种评分系统在3、6、12个月的预测准确性。改良Bauer评分、修订Tokuhashi评分、Linden评分、Tomita评分、骨骼肿瘤研究组列线图和新英格兰脊柱转移瘤评分预测生存的AUC略弱(范围0.464-0.659),Katagiri-New评分预测1年生存的AUC最高(0.708;范围0.619-0.798)。研究提示常用模型预测肺癌脊柱转移术后生存有局限性且低估生存,Katagiri-New评分预测1年生存表现最佳。

要点

  • 常用评分系统预测肺癌脊柱转移术后生存的AUC略弱,范围0.464-0.659。
  • Katagiri-New评分预测1年生存的AUC最高,为0.708(范围0.619-0.798)。
  • 决策曲线分析显示Katagiri-New评分净获益大于对所有患者或不对任何患者改变管理策略。

核心结论

  • 研究提示最常用的模型在预测肺癌脊柱转移脊柱手术患者生存方面有局限性,并低估生存。
  • 在该肺癌患者样本中,Katagiri-New评分系统预测1年生存表现最佳。

研究设计与样本

  • 回顾性病例系列,纳入2019至2021年两个中心接受脊柱手术的肺癌脊柱转移患者166例(平均年龄58.98±10.94岁;男105例,女61例)。
  • 计算最佳AUC评估七种候选评分系统在3、6、12个月的准确性,并使用校准和决策曲线分析进一步验证。

主要发现

  • 166例患者术后中位生存期为12.87±0.93个月。
  • 改良Bauer评分、修订Tokuhashi评分、Linden评分、Tomita评分、骨骼肿瘤研究组列线图和新英格兰脊柱转移瘤评分预测3、6、12个月生存的AUC略弱(范围0.464-0.659)。
  • Katagiri-New评分预测肺癌患者1年生存的AUC最高(0.708;范围0.619-0.798)。
  • 决策曲线分析显示Katagiri-New评分净获益大于对所有患者或不对任何患者改变管理策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Retrospective case series. OBJECTIVE: To investigate the accuracy of seven scoring systems for the prediction of survival in lung cancer patients with spinal metastases (SPM). SUMMARY OF BACKGROUND DATA: Although survival scoring systems have been developed for surgical decision-making, the reliability and validity of these models are unclear for specific cancer types. As the prevalence of patients with lung cancer increases, it is imperative to determine the accuracy of these models for lung cancer patients with SPM. MATERIALS AND METHODS: This is a retrospective study of a cohort of lung cancer patients with SPM who underwent spine surgery between 2019 and 2021 at two centers. The optimal area under the curve (AUC) was calculated to evaluate the accuracy of seven candidate scoring systems at 3, 6, and 12 months. Calibration and decision curve analysis was used for further validation. RESULTS: A total of 166 patients (mean age: 58.98±10.94; 105 males and 61 females) with SPM were included. The median postoperative survival was 12.87±0.93 months. The modified Bauer score, revised Tokuhashi score, Linden score, Tomita score, the Skeletal Oncology Research Group nomogram, and the New England Spinal Metastasis Score in prediction survival at 3, 6, and 12 months showed a slightly weaker AUC (range 0.464-0.659). The AUC of the Katagiri-New score in predicting 1-year survival for lung cancer patients was the highest (0.708; range 0.619-0.798). The decision curve analysis showed that the Katagiri-New score led to a greater net benefit than the strategies of changing management for all patients or none of the patients. CONCLUSIONS: This study suggests that the most commonly used models have limitations in predicting survival in patients undergoing spinal surgery for metastatic lung cancer and underestimate survival. In this sample of lung cancer patients, the Katagiri-New Scoring system score had the best performance in predicting 1-year survival. LEVEL OF EVIDENCE: 4.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Yan Y, Zhong G, Lai H, et al. Comparing the Accuracy of Seven Scoring Systems in Predicting Survival of Lung Cancer Patients With Spinal Metastases: An External Validation From Two Centers. Spine (Phila Pa 1976). 2023. PMID: 37350732. doi:10.1097/BRS.0000000000004576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。